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ABSTRACT
 
Pharmacy practice has changed generously as of late. 
The professionals have the chance to contribute 
straightforwardly to patient care so as to lessen 
morbimortality identified with medication use, 
advancing health and counteracting diseases. 
Healthcare associations worldwide are under 
significant weight from expanding patient interest. 
Lamentably, a fix isn't constantly conceivable 
especially in this period of chronic diseases, and the 
job of doctors has turned out to be restricted to 
controlling and vindicating indications. The 
expanding population of patients with long haul 
conditions are related with significant levels of 
morbidity, healthcare expenses and GP overload. 
Clinical pharmacy took over an aspect of medical 
care that had been partially abandoned by 
physicians. Overburdened by patient loads and the 
explosion of new drugs, physicians turned to 
pharmacists more and more for drug information, 
especially within institutional settings. Once 
relegated to counting and pouring, pharmacists 
headed institutional reviews of drug utilization and 
served as consultants to all types of health-care 
facilities. In case, the clinical pharmacists are active 
people of the care team, they increase efficiency by: 
Providing critical input on medication use and 
dosing. Working with patients to solve problems with 
their medications and improve adherence. 
 
Keywords: Chronic care, cardiovascular disease 
prevention, diabetes care, inflammatory bowel 
disease, pharmacy intervention 
 
BACKGROUND 
Clinical pharmacology is a professional 
discipline that combines basic 
pharmacology and clinical medicine. A 
clinical pharmacist offers invaluable 
support in the development of a final 
prescription with better patient 
management and enhanced safety [1]. Its 
development began in the early 1950s, 
primarily as a result of the efforts of Harry 
Gold. Pharmacist rounding with inpatient 
hospital services has been traced to the 
University of Kentucky in 1957 [1, 2]. 
Drug therapy was becoming much more 
complex. Graham Calder pioneered a new 
role for pharmacists on hospital wards in 
Aberdeen [3]. The role of clinical 
pharmacists underwent important changes 
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from the 1960s through 1990s as their 
participation in direct patient care 
increased. In the early 1970s, federal 
funding assisted with greatly expanding 
clinical pharmacy faculty in Colleges of 
Pharmacy [4]. Pharmacy education 
debated where clinical pharmacy fit within 
pharmacy training. The AACP 
spearheaded an effort to examine this 
issue. Till then, two full generations of 
pharmacists have been educated and 
trained after the general adoption of the 
aims of clinical pharmacy [4, 5]. ACPE 
has revised the standards for colleges and 
schools of pharmacy several times since 
2000. ACPE Standards 2016 go into effect 
July 1, 2016. To some extent, pharmacy 
took over an aspect of medical care that 
had been partially abandoned by 
physicians [6]. Overburdened by patient 
loads and the explosion of new drugs, 
physicians turned to pharmacists more and 
more for drug information, especially 
within institutional settings. A clinical 
pharmacist often has a somewhat different 
approach to the use of drugs and may give 
valuable supplementary information about 
for example interactions, during the 
physician’s decision-making process 
concerning potential changes of and the 
follow-up of the medication [7, 8]. The 
concept of pharmaceutical care 
emphasizes the pharmacists’ responsibility 
to pursue the best possible patient 
outcomes of medication therapy [9]. They 
possess in-depth knowledge of 
medications that is integrated with a 
foundational understanding of the 
biomedical, pharmaceutical, socio-
behavioral, and clinical sciences [10]. To 
accomplish wanted therapeutic goals, the 
clinical pharmacist applies proof based 
therapeutic guidelines, developing 
sciences, rising advancements, and 
important lawful, moral, social, social, 
financial, and proficient standards 
[11−13]. In understanding, clinical 
pharmacists accept accountability and 
responsibility for overseeing medication 
therapy in direct patient consideration 
settings, in the case of rehearsing freely or 
in meeting or joint effort with other 
healthcare professionals [14, 15]. Their 
functions encompass comprehensive 
medication management (i.e., prescribing, 
monitoring, and adjustment of 
medications), nonpharmacologic guidance, 
and coordination of care. Interdisciplinary 
collaboration allows pharmacists 
opportunities to provide direct patient care 
or consultations by telecommunication in 
many different clinical environments, 
including disease management, primary 
care, or specialty care [16−19]. 
Pharmacists may manage chronic or acute 
illnesses associated with endocrine, 
cardiovascular, respiratory, 
gastrointestinal, or other systems [20]. 
Clinical pharmacist researchers generate, 
disseminate, and apply new knowledge 
that contributes to improved health and 
quality of life [21−24]. Inside the 
arrangement of healthcare, clinical 
pharmacists are specialists in the 
therapeutic utilization of medications. 
They routinely give medication therapy 
assessments and suggestions to patients 
and healthcare professionals [25, 26]. 
Clinical pharmacists are an essential 
wellspring of logically legitimate data and 
counsel in regards to the sheltered, proper, 
and financially savvy utilization of 
medications [27, 28]. They get restorative 
and medication history, check medication 
blunders including prescription, dispensing 
and administration mistakes, distinguish 
drug interactions, screen ADR, propose 
individualization of measurement routine, 
give patient counseling, and so forth 
[29−35]. They also provide information 
about the use of drugs and medical devices 
like inhaler, insulin pen, eye drops, nasal 
sprays, etc. [36]. Participation of a clinical 
pharmacist in ward/ICU rounds and 
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clinical discussions helps to identify, 
prevent or reduce drug interaction and 
ADR [29], [37−39]. 
 
Figure 1: Clinical pharmacy offers chronic care services. The integration of clinical 
pharmacists into primary care clinics could have positive effects on the clinical outcomes of 
patients in glycemic control, blood pressure, lipid profile, in accordance with current 
guidelines (Source: Strategies for Chronic Care). 
 
INTRODUCTION 
Population aging has increased the burden 
of chronic diseases globally. There are 
both ethical and reasonable goals to 
address health inequity issues identified 
with chronic disease management for 
people with social multifaceted nature, 
existing programs regularly don't fittingly 
address the necessities of these people. 
This prompts low degrees of support in 
programs, imperfect chronic disease 
management, and higher healthcare usage 
[40]. Unlike acute conditions, chronic 
diseases require consistent care and 
management outside of the healthcare 
setting, in the community or primary care 
setting, in terms of medication, lifestyle 
management, and health behavior 
modification [41−45]. It is ordinarily a 
multi-segment intercession that 
incorporates medication treatment audit, 
patient medication education, medication 
monitoring, immunizations, illness self-
care and support, or potentially endorsing 
position. Patients who take different 
medications because of chronic malady 
have a high danger of drug duplication, 
interaction, or unfavorable reactions, 
which could bring about broadened 
emergency clinic stays and greater 
expenses [46]. To build the security and 
viability of treatment, these patients must 
have explicit needs met, with respect to 
fitting medication use [47]. Studies have 
demonstrated that incorporating 
pharmacists into mobile clinics can 
improve chronic infection the executives 
and ideal utilization of medications [48]. 
Furthermore, pharmacist commitment in 
patient care may diminish tasteless 
medication use, unequivocally in the old. 
A study in Canada uncovers the degree of 
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patients tolerating an improper medication 
drop basically after medication review and 
improvement by a group that consolidated 
a pharmacist [49]. Contrasted with regular 
care, pharmacist-drove care was related 
with comparable frequencies or paces of 
office, earnest care or ED visits, and 
hospitalizations and medication adherence, 
expanded the number or portion of 
medications got and improved study-
selected glycemic, circulatory strain, and 
lipid objective achievement [50]. Another 
recent study shows telehealth-based 
chronic disease management program 
including clinical pharmacy specialists 
imparted statistically significant 
improvements in diabetes and 
hypertension outcomes along with 
clinically significant improvements in the 
areas of lipid management and tobacco 
cessation [51]. 
 
Diabetes Care 
As the seventh-leading cause of death in 
the US, diabetes can lead to various health 
complications such as blindness, kidney 
disease, amputations, and heart disease. 
The worldwide existing prevalence of DM 
is about 425 million people, of whom 279 
million are in urban areas and 146 million 
are in rural zones [52]. The IDF estimates 
that by 2040, one in 10 adults (642 
million) will have diabetes. Around 50% 
(212.4 million) of patients are unaware of 
their diabetes. More than 12% of total 
global health expenditure goes to diabetes, 
according to IDF [53]. Annual worldwide 
economic cost of diabetic care was 
calculated at $727 billion in year 2017 
which is predicted to be $776 billion for 
year 2045 respectively [54]. Currently, 
more than 230 million Asian individuals 
are living with diabetes, accounting for 
approximately 55% of the world’s diabetic 
population. China and India collectively 
are home of nearly 110 million diabetic 
patients [55]. It is a risk factor for CVD 
and has been related with 2-to 4-fold 
higher mortality [56] and another study 
says that half of all diabetic demise was 
expected to CVD [57]. The quantity of 
deaths brought about by diabetes in the age 
scope of 60–99 years in 2017 was 
3,200,000 [58]. About portion of diabetes-
related mortality (48%) happens in people 
more youthful than 60 years and it keeps 
on diminishing future by 6–8 years in 
people analyzed at 50 years old years [59]. 
Over 35% patients didn't get any diabetes 
education, while 30% diabetic patients 
were compliant with drug regimens and 
the non-compliance was higher among the 
lower socioeconomic groups [60]. 
Pharmacist may provide a face-to-face 
counseling regarding knowledge on 
diabetes, self-monitoring of blood glucose, 
regular checkup of systolic blood pressure, 
body weight, and serum cholesterol levels. 
The pharmacist may also counsel 
regarding non-pharmacological 
management strategies such as diet 
control, exercise therapy, and early 
identification of symptoms of 
hypoglycemia (blurred vision, rapid 
heartbeat, sweating, fatigue, headache, 
dizziness, trouble thinking, seizures, and 
coma) and its management. In a 
satisfaction survey of 24 providers or 
clinical pharmacists, nearly 90% had 
favorable responses toward the protocol 
and its effect on access to and quality of 
care [61]. Management of DM remains a 
significant challenge in the US, as 
estimates indicate that greater than 40% of 
diabetes patients are uncontrolled with a 
HbA1c. Diabetic patients who received 
care from the collaborative team, including 
a clinical pharmacist, had improvement in 
most key indicators of diabetes like 
HbA1c, in both high- and low- income 
countries and in both urban and rural areas 
[62−71]. Emphasizing medication 
adherence, particularly for patients with 
longer duration of diabetes and those with 
multiple comorbid diseases should be 
strongly considered in future diabetes 
management programs implemented to 
improve glycemic control in patients with 
type 2 diabetes [72]. A mobile phone text 
message can serve as a simple and cost-
effective option in improving medication 
adherence and clinical outcomes by 
providing information between clinic visits 
has been reported (Figure 2) [73, 74]. A 
report from the National Diabetes 
Commission suggested that an 
inappropriate attitude of health care 
professionals toward diabetes could lead to 
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poor patient outcomes [75]. In educational 
program, a clinical or community 
pharmacist can improve adherence by 
giving medication consultation 
administration, making an individualized 
patient timetable on administration times 
and dosage of every medication, 
instructing the patient on the significance 
of medication adherence, dietary 
adherence and exercise on better glycemic 
control, offering guidance on the best way 
to diminish adverse effects of medications, 
and furthermore by instructing how to take 
medications in the holy month of Ramadan 
or different religious fasting, and how to 
utilize pill boxes and diary logs to decrease 
absent mindedness. Writing demonstrates 
various interventional studies including 
pharmacist-based educational 
intercessions, indicating clinically 
noteworthy enhancements in the clinical 
results of the diabetes patients [76].
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Figure 2: Telemonitoring model for providing clinical pharmacy services to patients with 
diabetes [62].
CVD Prevention 
Hypertension is the single most important 
risk factor for CVD and a key driver of 
global disease burden [77]. It is a major 
risk factor for CHD, stroke, retinopathies, 
and renal dysfunction. 18 million people 
die each year from CVDs, an estimated 
31% of all deaths worldwide [78]. Of these 
deaths, 85% are due to MI and stroke [79]. 
CVD is currently the leading cause of 
morbidity and mortality and over 80% 
occur in LMICs [80]. Nearly 50% patients 
with chest pain related to exercise have 
obstructive coronary artery disease [81]. 
Coronary artery spasm plays an important 
role in the pathogenesis of IHD, including 
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angina pectoris, MI, and sudden death, 
occurring most often from midnight to 
early morning [82]. A study of 1,015 
patients with stable coronary artery disease 
showed a 4.4-fold increase in the risk of 
stroke and a 3.8-fold increase in the risk of 
death among patients who self-reported as 
nonadherent [83]. IHD has topped the list 
of causes of years of life lost for more than 
a decade, highlighting the shift in the 
global burden of disease from 
communicable to chronic disease. Risk 
factors for CVD, including raised blood 
pressure, hypercholesterolaemia and high 
BMI, are among the most important 
contributors to DALYs [84]. CVD claimed 
death of some 900,000 death in US in 
2016 [85]. BP is as yet uncontrolled in half 
of the US population with hypertension. 
Moreover, BP can remain ineffectively 
controlled regardless of up to six doctor 
visits for each year [86]. Crosswise over 
South Asia, in general hypertension 
prevalence is assessed to be 27%. 
Prospective Urban Rural Epidemiology 
study has demonstrated over half are 
ignorant of it and up to 80% of 
hypertensive patients have low adherence 
to medication. Uncontrolled BP was 
discovered over half in Bangladesh, 70% 
in Pakistan and practically 60% in Sri 
Lanka [87]. The goals of treatment of 
hypertension are to restrict target organ 
damage, in this manner decreasing the 
horribleness and mortality related with the 
disease [88]. Numerous factors including 
financial status, conviction about 
medications, comorbidity, accessibility of 
medications, access to healthcare, level of 
health proficiency, number of medications, 
duration of therapy, age, gender, culture, 
educational status, and learning of the 
disease and treatment have been related 
with the pace of adherence. Absence of 
medication accessibility, low degree of 
mindfulness about the disease and 
treatment, failure to manage the cost of 
prescriptions, question in western drug, 
and more trust on traditional and spiritual 
healers are exceptionally normal in the 
rural population [89]. Non-drug therapies 
have been shown to lower BP, enhance 
antihypertensive drug efficacy, and 
decrease cardiovascular risk. All patients 
with hypertension and those in the 
prehypertensive category should be 
advised to make life-style modifications in 
addition to any pharmacologic treatment 
that they receive [90]. Surprisingly, 60%- 
80% of the population around the world 
(according to WHO) are partially or fully 
dependent upon herbal drugs for primary 
healthcare [91]. Interactions of certain 
ingredients in supplements with other anti-
hypertensive and cardiovascular 
arrangements are well-reported [92]. 
Green tea demonstrated 85% abatement in 
plasma concentration of nadolol, for 
instance [93]. The pharmacist may assume 
a significant job in primary and secondary 
prevention of cardiovascular diseases, 
chiefly through patient education and 
counseling, drug safety management, 
medication audit (survey of both drug-food 
and drug-drug cooperation), monitoring 
and reconciliation, discovery and control 
of explicit cardiovascular risk factors (e.g., 
circulatory strain, blood glucose, serum 
lipids) and clinical outcomes [94]. 
Pharmacist intervention can increase 
patients' knowledge about their condition 
in a way that positively modifies their 
beliefs about medicines, increased 
medication intensification without 
significant change in medication 
adherence, modify factors affecting 
adherence, improve adherence and patient 
QoL by reducing BP levels in patients 
treated with antihypertensive agents, 
increased referral acceptance (Figure 3) 
[86], [95−99]. Interventions that were 
most effective included combinations of 
more convenient care, information, 
reminders, self-monitoring, reinforcement, 
counseling, family therapy, psychological 
therapy, crisis intervention, manual 
telephone follow-up, and supportive care 
[83]. Weight loss has been noted to modify 
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risk factors via improving insulin 
sensitivity, reducing inflammation, 
decreasing blood pressure and modifying 
the lipid profile [100]. It is astonishing that 
7–28% of patients with coronary heart 
disease still smoke, but around half of 
smokers are planning to quit [101]. The 
World Bank proposes that around 180 
million tobacco related deaths could be 
forestalled among now and 2050 if 
grown-up tobacco utilization diminished 
by half by 2020 [102]. A clinical 
pharmacist prepared for smoking 
cessation counseling can play a key job 
in giving such mediations, including the 
evaluation of pharmacotherapy 
interactions with tobacco smoke [103]. 
Prescription smoking cessation 
medications include bupropion and 
varenicline [104]. A recent Canadian 
survey shows that pharmacist-led 
intervention resulted in more than 70% 
of patients using nicotine replacement 
therapy for smoking cessation [105].
 
 
Figure 3: Effects of pharmacist’s intervention on humanistic, clinical and economic 
outcomes in patients with CVD [94]. 
 
Obesity Management 
In each and every nation on the earth, the 
rate of obesity is rising constantly with 
coronary artery disease, hypertension, type 
2 diabetes mellitus, respiratory disorders 
and dyslipidemia [106]. The WHO 
assessed that in 2016 more than 1.9 billion 
grown-ups were overweight (almost 40% 
of the population) and more than 650 
million (13% of the population) were 
people with heftiness [107]. Globally, the 
yearly cost of corpulence related diseases 
has come to $2 trillion as per an ongoing 
report by McKinsey Global Institute [108]. 
Corpulence expands cardiovascular risk 
through risk factors, for example, 
expanded fasting plasma triglycerides, 
high LDL cholesterol, low HDL 
cholesterol, raised blood glucose and 
insulin levels and hypertension [109, 110]. 
Likewise, obesity causes cerebral 
vasculopathy, gallbladder lithiasis, 
arthropathy, ovarian polycytosis, sleep 
apnea syndrome, and a few neoplasms 
[111]. Successful obesity treatment plans 
incorporate diet, exercise, behavior 
modification (with or without drug 
treatment), and/or surgical intervention 
(Figure 4) [112]. Prior to recommending 
any treatment, the clinician must evaluate 
the patient for the presence of secondary 
causes of obesity, such as thyroid 
dysfunction [113, 114]. If secondary 
causes are suspected, then a more 
complete diagnostic workup and 
appropriate therapy is important. The 
clinician should then evaluate the patient 
for the presence and severity of other 
obesity-related diseases, evaluating 
appropriate lab tests as indicated. Based on 
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the outcome of this medical evaluation, the 
patient should be counseled on the risks 
and benefits of available treatment options 
(along with obesity‐related comorbidities, 
including T2D prevention, and 
improvements in dyslipidemia, 
hyperglycemia, osteoarthritis, stress 
incontinence, GERD, hypertension, and 
PCOS [115, 116]. If obesity is present 
without other comorbid conditions, then 
the goal would be absolute weight loss. In 
the presence of comorbid conditions, 
relatively small reductions in total body 
weight can have significant effects on 
comorbidity [117]. 
  
 
Figure 4: 2013 AACE Obesity Treatment Algorithm [118]. 
 
Pharmacists, regularly viewed as one of 
the most dependable and open healthcare 
professionals, are in a perfect world 
arranged to give counseling to weight and 
way of life management. All around 
prepared pharmacists to perform 
fundamental physical evaluations, for 
example, weight, abdomen circumference, 
blood glucose monitoring, and 
pharmacotherapy counseling, while extra 
training could be effectively acquired for 
administrations that would incorporate 
dietary counseling, direction on physical 
activity, and behavioral counseling [108], 
[119, 120]. As pharmacists currently do 
not have a well-identified role in obesity 
management, but study results display that 
pharmacist intervention was beneficial 
[121]. According to Canadian Pharmacists 
Journal, 2016 pharmacist prescribing 
resulted in >3-fold more patients achieving 
target LDL-c levels [122]. Pharmacists 
who identify and treat patients with 
dyslipidemia, including those with 
inadequately controlled LDL cholesterol 
levels, are better than physicians at getting 
patients to goal [123]. Studies have 
demonstrated that Pharmacist led 
interventions, including lipid clinics, can 
help patients achieve these more 
aggressive goals [124, 125]. 
 
Asthma and Chronic Obstructive 
Pulmonary Disease Management 
Asthma and COPD are common chronic 
conditions that comprise nearly 80% of 
direct health care costs associated with 
respiratory diseases in the EU [126]. In the 
UK alone, 5.4 million patients are 
currently receiving treatment for asthma; 
of these, 1.1 million are children. Over 
three million people die of COPD 
worldwide each year, an estimated 6% of 
all deaths worldwide [127]. It is the second 
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most common reason for emergency 
hospital admission. According to WHO, 
COPD has become the fourth leading 
cause of mortality in the US. It is 
estimated to become the fifth leading 
cause of disease burden in 2020 [128]. In 
2015 alone, the death toll due to asthma 
was 383,000 globally [129]. One in five 
individuals with a diagnosis of COPD, 
asthma, or both asthma and COPD in 
primary care settings have asthma-COPD 
overlap [130]. In COPD, the outpatient 
therapeutic and management goals are to 
reduce symptoms and risks from 
exacerbations, and to maintain drug 
therapy. In contrast with asthma, COPD is 
a disease caused by chronic and often daily 
exposure to noxious particles or gases. The 
small airways in COPD are gradually 
destroyed leading to chronic bronchitis and 
emphysema [131]. Ideal pharmacological 
treatment including fast treatment of 
exacerbations, can improve symptoms, 
diminish exacerbation recurrence, and 
improve practice resilience, while poor 
medication adherence and imperfect 
inhaler technique contrarily sway 
outcomes [132]. Adherence to breathed in 
medication is poor in reality and shows 
extraordinary inconstancy, going from as 
low as 20% to over 60% [133]. To 
improve adherence, the therapeutic choices 
ought to be talked about with the patient 
and should contemplate their lifestyle 
factors, demographic attributes (age, co-
morbidities, physical confinements, mental 
and cognitive status), and pharmacological 
factors (polypharmacy regimens) to pick 
the best inhaler device for that patient 
[134]. Pharmacist-led comprehensive 
therapeutic interchange program of COPD 
inhalers may provide 30% pharmacy cost 
savings, improved medication adherence, 
knowledge of disease, decrease the 
number of prescriptions for exacerbations 
for these patients, and reduces 30-day 
readmission rate [135−138]. A pharmacist-
driven spirometry service was associated 
with quality testing results, identified 
respiratory disease abnormalities, and 
helped modifications of pulmonary drug 
regimens based on evidence-based 
guidelines [137]. Despite advances in 
inhaler device technology, estimates of 
those making inhaler errors range up to 
90% of patients irrespective of the device 
type used. Poor inhaler technique 
accounted for over €750 million in direct 
and indirect costs in 2015 in the UK, Spain 
and Sweden [139]. By providing 
pharmaceutical care to patients with 
asthma, the pharmacist can help them to 
achieve treatment goals, e.g. improvement 
of disease control and reduction of asthma 
symptoms, exacerbations and medication-
related side effects [140]. Step up therapy 
contained expanding or beginning 
corticosteroid/long-acting beta agonist mix 
inhaler; corticosteroid inhaler; short-acting 
muscarinic antagonist inhaler; oral 
corticosteroid; oral montelukast; or long-
acting muscarinic antagonist inhaler. Step 
down of therapy included diminishing or 
halting corticosteroid/long-acting beta 
agonist mix inhaler; corticosteroid inhaler; 
or long-acting muscarinic antagonist 
inhaler. The pharmacist directed exercises, 
for example, giving asthma activity plans, 
instructing patients, prescribing to step 
up/down therapy, auditing inhaler 
technique and making other significant 
proposals, for example, gadget changes 
(e.g., dry-powder to metered-dose inhaler) 
[141]. Polypharmacy is oppressive and 
related with patients hospitalized with 
intense intensifications. It is conceivable 
that rehashed pharmacist intervention to 
guarantee ideal pharmacotherapy and limit 
adverse effects, with an immediate connect 
to a consultant respiratory physician, and 
the patient's GP, may prompt improved 
results [142]. The interventions identified 
focused on key areas of asthma and COPD 
management and support including: 
assessment of current symptoms; 
assessment and rectification of inhaler 
technique; identification of medication-
related problems; medication adherence; 
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provision of written and oral education materials; smoking cessation (Fig 5) [143]. 
 
 
Figure 5: Unifying model showing key influences on successful delivery of smoking cessation 
support by pharmacists [144]. 
 
Osteoporosis 
Around the world, it is evaluated that 1 of 
every 3 women over the age of 50 will 
encounter osteoporotic fractures, just as 1 
out of 5 men [145]. The predominance of 
osteoporosis is anticipated to ascend in the 
US from around 10 million individuals to 
in excess of 14 million individuals by 
2020 [146]. In 2015, direct medical costs 
totaled $637.5 million for lethal fall 
injuries and $31.3 billion for nonfatal fall 
injuries. During that year, hospitalizations 
cost a normal of $30,550 per fall 
affirmation, totaling $17.8 billion. By 
2025, the expense of fractures in the US is 
relied upon to surpass $25 billion every 
year to treat in excess of 3,000,000 
anticipated fractures [147]. Like other 
chronic diseases, osteoporosis has 
struggled with prescription non-adherence, 
bringing about an expanded danger of 
fractures and all-cause mortality. The gaps 
in osteoporosis management are all well-
documented: (a) most patients at high 
chance for break are not recognized for 
treatment, and (b) adherence to 
osteoporosis pharmacotherapy is imperfect 
[148]. About half osteoporosis patients are 
non-disciple to medications. Besides, 
around 50–70% of the patients stop their 
osteoporosis medications inside the main 
year of commencement, which results in 
expanded horribleness and mortality [149]. 
In October 2010, the US FDA issued a 
safety communication regarding the risks 
of atypical fractures of the femur, with 
bisphosphonates drugs, the safety 
communication appeared to have 
influenced osteoporosis utilization in 
Medicaid recipients [150].  
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Figure 6: Mapping the factors influencing adherence and adherence strategies onto the 
medication-taking process in patients with osteoporosis [151]. 
 
High patient cost and safety concerns are 
barriers for nearly 60% patients [152]. 
Improved osteoporosis medication 
adherence can reduce osteoporosis-related 
health care costs by preventing fractures. 
Persistent pharmacotherapy for 
osteoporosis is necessary to prevent 
osteoporotic fractures and to reduce 
osteoporosis-related health care costs 
[153]. Treatment strategies of osteoporosis 
include non- pharmacological treatment - 
diet rich of calcium and vitamin D, healthy 
lifestyle, proper exercise plan, and 
pharmacological therapy [154]. BMD 
monitoring after initiating anti-
osteoporosis therapy in the routine clinical 
practice setting [155]. Hypercalciuria, 
malabsorption of calcium, 
hyperparathyroidism, vitamin D 
deficiency, hyperthyroidism, Cushing’s 
disease, and hypocalciuric hypercalcemia 
attributed to secondary causes to more 
than 30% women. Disorders of calcium 
metabolism and hyperparathyroidism 
contributed to nearly 80% of the secondary 
causes [156]. Hormone replacement 
therapy (HRT) is not first-line therapy 
position for osteoporosis, but is best for 
prevention of osteoporosis [157]. 
However, different types of estrogen or 
progestogen, as well as different 
formulations, doses, timing of initiation, 
durations of therapy, and patient 
characteristics, may play different roles in 
the effects of HRT [158]. Pharmacist-
physician collaboration is associated with 
higher treatment rates of osteoporosis 
[159]. Physicians and pharmacist should 
invest time to educate patients about the 
potential side effects and box warnings of 
estrogen use. Routine women wellness 
exams should also be focused on the 
development of any malignancies or 
adverse effects of hormone replacement 
therapy given a positive history. The 
pharmacist can play an important role at 
multiple levels: supporting patients in 
treatment, by providing information on the 
disease, its treatment, proper use of 
medication, adherence and persistence, as 
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well as raising awareness for the 
prevention of osteoporosis and identifying 
patients at risk [160]. The counseling 
should include educating and assessing the 
patient for proper use of estrogen 
medication therapies as they may be 
prescribed in many various preparations of 
oral, transdermal, vaginal insert, and topic 
vaginal creams for positive patient 
compliance and adherence to therapy 
[147]. 
 
Inflammatory Bowel Disease  
Inflammatory bowel disease (IBD) is a 
group of inflammatory conditions of the 
colon and small intestine. The two most 
common diseases are ulcerative colitis and 
Crohn's disease (CD). Crohn's disease can 
cause inflammation in any part of the 
digestive tract. Ulcerative colitis (UC) is 
an idiopathic inflammatory condition of 
the colon which results in diffuse friability 
and superficial erosions on the colonic 
wall associated with bleeding [161]. 
Although these diseases have 
undetermined etiology, research advances 
have outlined some of the pathways by 
which they occur: a) genetic predisposition 
associated with the environment induces a 
disruption of the intestinal microbial flora, 
b) the epithelial cells and the immune 
system of the intestine itself determine the 
risk of developing the disease [162]. 
Treatment of both, IBD and IBD 
associated pain is challenging. The 
mainstay of IBD treatment includes 
systemic immunosuppressive medications, 
such as corticosteroids, anti-tumor TNF 
antibodies or immunomodulators. 
Furthermore, the management of an acute 
flare differs from the strategies for 
maintenance of remission [163]. A total of 
about 66,000 US residents with a new IBD 
diagnosis each year, since 2015 [164]. 
Direct costs (including consultations, 
drugs, hospitalization and surgery) of UC 
amount to $3.4 to $8.6 billion in the US 
and €5.4 to €12.6 billion in EU [165]. The 
prevalent populations of patients with CD 
or UC in the UC in 2016 are expected to 
incur lifetime total costs of $498 billion 
and $377 billion, respectively [166]. IBD 
is a relapsing–remitting condition that 
causes inflammation and ulceration in the 
bowels, affecting approximately 500,000 
people in the UK [167]. 
 
 
Figure 7: The seven sections of the 2019 IBD Standards [167]. 
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The increasing incidence of IBD in 
developing countries parallels the 
westernization of diet, which includes 
higher calorie intake, especially from 
sugar, refined carbohydrates, animal 
proteins and ultra-processed foods and a 
lesser intake of fiber and fruits [168,169]. 
Incidence rate of IBD is stabilizing in 
some developed countries; however, the 
incidence rate is increasing in developing 
countries such as Asia and Eastern Europe 
[170]. Anxiety and depression are the most 
common psychological disorders in 
patients with IBD [171]. IBD is associated 
with significantly increased MI compared 
with non-IBD patients [172]. Patients with 
IBD are also at risk for asthma or COPD 
and bronchiectasis [173, 174]. Sacroiliitis, 
an inflammatory arthropathy associated 
with ankylosing spondylitis, is found in 
patients with IBD but may go undiagnosed 
[175]. IBD patients showed increased risk 
for lymphoma and biliary cancer [176]. 
The general objectives of treatment are to 
instigate and maintain remission, limit 
intricacies and sickness manifestations, 
and improve overall QoL. Customized 
IBD pharmacist adherence counseling, in 
light of the Health Beliefs Model of 
prescription recognition, may expand drug 
adherence. Instruction utilizing pamphlets 
and ad hoc physician training improved 
information yet not adherence [177]. IBD 
patients, fundamentally those having UC, 
need medications for a mind-blowing 
duration with periodic dosing and 
occasionally, enemas and infusions may 
likewise be required. Treatment without 
adherence is exceptionally viewed as the 
noteworthy factor for relapse occurrence 
[178]. Prescription nonadherence in IBD 
can be improved through a solitary 
customized counseling session by IBD 
pharmacist adherence counseling (IPAC) 
intervention, and the advantage was sturdy 
for a long time [179]. In addition to the 
ailment, these patients are likewise dealt 
with powerful medications like steroids 
and biological agents, which have a large 
group of adverse effects. Along these 
lines, the significance of the pharmacist 
who ought to be alert for any adverse 
reaction [180]. Pharmacist-led drug 
monitoring clinics measure thioguanine 
nucleotides and thiopurine 
methyltransferase levels four weeks after 
treatment with thiopurines is started to 
optimize outcomes [181]. In the event that 
insurance coverage can't be acquired for 
the chose biologic response modifiers, the 
pharmacist recognizes and talks about 
elective alternatives with the GI team; a 
portion of these choices may incorporate 
changing to another model operator or 
selecting patients in medicine assistance 
programs. When insurance coverage of the 
medicine is verified, the pharmacist 
teaches the patient on self-administration, 
stability and storage prerequisites, and 
potential adverse effects. Additionally, the 
pharmacist features the noteworthiness of 
consistence with laboratory monitoring 
and reviews the significance of speaking 
with the GI team in the event of potential 
infection, exacerbating sickness control, or 
issues getting or utilizing the medicine. 
The IBD pharmacist has a key job in the 
administration of IBD patients 
contributing not exclusively to drug 
monitoring, recommending, and wellbeing 
yet in addition allowing more prominent 
limit in the physician's, frequently 
profoundly stretched IBD clinics [182]. 
Past drug therapy coordination from start 
to finish, the pharmacist assumes a 
functioning job in helping with medicine 
reconciliation and guaranteeing patients 
are present on essential immunizations 
[183]. 40% of patients with CD do not 
respond to treatment with biologics, 30% 
to 50% achieve complete remission after 
six months and 30% of patients maintain 
the response for 12 months with continual 
treatment. Current strategies to overcome 
loss of response involve increasing the 
dose, decreasing the interval between 
administrations or switching to an 
alternative agent [181]. 
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CONCLUSION 
The pharmacist's fundamental obligation is 
to augment positive results of drug therapy 
and limit drug misadventures. Patient 
therapy should bring about the 
achievement of definite results that 
improve the patient's QoL. Until now, 
various examinations have discovered an 
expanded pace of clinic admission rates 
optional to medicine rebelliousness as well 
as adverse drug reactions. The genuine 
number of DRPs requiring clinic 
admission might be higher than revealed 
because of absence of documentation, 
further underestimating the issue. Initially, 
gathering and deciphering pertinent patient 
information, identifying patient social 
insurance needs, and planning a DRP 
rundown might challenge for the 
pharmacist. Preventive or chronic 
consideration is a challenge that ought to 
be embraced by social insurance suppliers 
in all training settings. Pharmacists should 
"seize the moment" to teach and insight 
patients with respect to these different 
points when the open doors emerge. 
Clinical pharmacists use populace 
wellbeing techniques to create chronic 
infection the management referrals for 
patients with uncontrolled chronic 
conditions. Open doors for pharmacists to 
help realize consciousness of 
recommendations and hazard factors for 
the development of disease, and instruct 
patients with regards to the advantages of 
prevention, happen every day. It is 
significant for the pharmacists on the 
"bleeding edge" to have a general 
comprehension of ebb and flow 
recommendations for screening and 
sickness prevention with the goal that they 
can give proper counseling and care to 
their patients. Also, pediatric clinical 
pharmacists have evolved over the last 2 
decades and have proven to be a key 
player in the multidisciplinary team. 
Although, there are ample of evidences of 
positive impact on clinical, humanistic and 
economic outcomes and the benefits of 
clinical pharmacists managing chronic 
conditions have been extensively 
published, their involvement in the 
multidisciplinary team providing care to 
patients with chronic cases, more high-
quality research is warranted. 
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